Department of Pathology, Medical Faculty, Charles University Hospital Pilsen, Charles University, Pilsen, Czech Republic.
Bioptická laboratoř, s.r.o., Pilsen, Czech Republic.
Cytopathology. 2020 Jul;31(4):288-291. doi: 10.1111/cyt.12831. Epub 2020 Jun 14.
It is generally acknowledged that interobserver variability for the histological diagnosis of endocervical adenocarcinoma (EA) subtypes is suboptimal. The recently proposed International Endocervical Adenocarcinoma Criteria and Classification (IECC) system is based on the presence of associated human papilloma virus (HPV) infection. It recognises HPV-associated EAs and non-HPV-associated EAs.
This prospective cytology-histology and molecular genetics-based study investigated the potential effect of IECC being applied to Papanicolaou (Pap) test with regard to the diagnostic accuracy of severe glandular lesions reported at least as adenocarcinoma in situ (AIS).
Out of 118 liquid-based cytology Pap tests with AIS+ lesion, complete information on follow-up biopsy and HPV status was available in 51 cases. AIS and EA category correlated with histologically confirmed AIS/EA in 88.5% (23/26) and 70.5% (12/17) of cases, respectively. Interestingly, 93% (40/43) of cases diagnosed as AIS/EA were HPV positive and 7% (3/43) were HPV negative (originating in the cervix, endometrium and adnexa).
Our findings suggest that this approach could possibly divide Pap tests containing severe glandular lesion into two groups: (a) robust diagnosis of HPV-associated EA and (b) non-HPV associated glandular lesions of heterogeneous origin, requiring further clinical preoperative diagnostic workup.
人们普遍认为,宫颈内膜腺癌(EA)亚型的组织学诊断存在观察者间变异性不理想的问题。最近提出的国际宫颈内膜腺癌标准和分类(IECC)系统基于人乳头瘤病毒(HPV)感染的存在。它识别 HPV 相关的 EA 和非 HPV 相关的 EA。
本前瞻性细胞学-组织学和基于分子遗传学的研究调查了在巴氏涂片(Pap)检测中应用 IECC 的潜在效果,研究内容是关于至少报告为原位腺癌(AIS)的严重腺上皮病变的诊断准确性。
在 118 例液基细胞学 Pap 试验中,有 AIS+病变,其中 51 例有关于随访活检和 HPV 状态的完整信息。AIS 和 EA 类别与组织学证实的 AIS/EA 分别相关 88.5%(23/26)和 70.5%(12/17)。有趣的是,93%(40/43)诊断为 AIS/EA 的病例 HPV 阳性,7%(3/43)HPV 阴性(起源于宫颈、子宫内膜和附件)。
我们的研究结果表明,这种方法可能将含有严重腺上皮病变的 Pap 试验分为两组:(a)HPV 相关 EA 的可靠诊断;(b)非 HPV 相关的、具有不同来源的腺上皮病变,需要进一步进行临床术前诊断评估。